Pentavalent Meningococcal Conjugate vaccine

EuBiologics, in collaboration with PATH, is developing an affordable pentavalent meningococcal conjugate vaccine (NmCV-5) targeting serogroups A, C, W, Y, and X for the Meningitis Belt in Sub-Saharan Africa. Phase I trials in South Korea demonstrated strong safety and immunogenicity superior to those of existing quadrivalent vaccines. EuBiologics aims to become the second WHO-prequalified pentavalent supplier by late 2027, offering competitive pricing aligned with Gavi’s vaccine investment strategy and an improved liquid multidose presentation. With previous RIGHT Foundation support, Phase II/III trials are now underway in The Gambia and Mali across multiple cohorts (ages 9 months to 29 years) to assess safety, immunogenicity, lot-to-lot consistency, and co-administration with routine vaccines, advancing WHO’s Defeating Meningitis by 2030 Global Road Map.